Literature DB >> 22161506

Low-dose probenecid selectively inhibits urinary excretion of phenolsulfonphthalein in rats without affecting biliary excretion.

Yong-Jun Shin1, Joo Hyun Lee, Ju-Hee Oh, Young-Joo Lee.   

Abstract

Renal organic anion transport systems play an important role in the excretion of anionic drugs and toxic compounds. Probenecid has been used as a potent inhibitor of urinary and biliary excretion of anionic compounds mediated by transporters such as organic anion transporters and multidrug resistance-associated protein 2 (Mrp2). The purpose of this study was to optimize the dose of probenecid required for selective inhibition of urinary excretion of anionic compounds in rats, without inhibition of biliary excretion. Phenolsulfonphthalein (PSP), a model anionic compound that is excreted in urine and bile, was intravenously administered to rats after intraperitoneal injection of different doses of probenecid (0, 0.2, 2, 10, 100, 200 and 400 mg kg(-1) ). Treatment with 100, 200 or 400 mg kg(-1) probenecid decreased both renal clearance (CLr ) and biliary clearance (CLb ) of PSP, whereas 0.2 mg kg(-1) probenecid did not have any effect. Probenecid administered at doses of 2 and 10 mg kg(-1) decreased only CLr . The median effective doses of probenecid for inhibiting CLr and CLb were 0.925 and 23.9 mg kg(-1) , respectively. These data suggest that a low dose of probenecid selectively inhibits urinary excretion of PSP that may be mediated by organic anion transporters, without affecting biliary excretion that may be mediated by Mrp2.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22161506     DOI: 10.1002/jat.1778

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  5 in total

1.  Probenecid protects against transient focal cerebral ischemic injury by inhibiting HMGB1 release and attenuating AQP4 expression in mice.

Authors:  Xiao-Xing Xiong; Li-Juan Gu; Jian Shen; Xian-Hui Kang; Yue-Ying Zheng; Si-Biao Yue; Sheng-Mei Zhu
Journal:  Neurochem Res       Date:  2013-12-07       Impact factor: 3.996

2.  Probenecid arrests the progression of pronounced clinical symptoms in a mouse model of multiple sclerosis.

Authors:  Nadine Hainz; Sandra Wolf; Artjom Beck; Stefan Wagenpfeil; Thomas Tschernig; Carola Meier
Journal:  Sci Rep       Date:  2017-12-08       Impact factor: 4.379

3.  Human Organic Anion Transporting Polypeptides 1B1, 1B3, and 2B1 Are Involved in the Hepatic Uptake of Phenolsulfonphthalein.

Authors:  Zhongmin Wang; Ying Li; Taotao Peng; Ying Su; Xiaoting Luo; Wanjun Han; Hongjian Zhang; Jianqing Ruan; Chunshan Gui
Journal:  ACS Omega       Date:  2021-12-16

4.  Probenecid-Blocked Pannexin-1 Channel Protects Against Early Brain Injury via Inhibiting Neuronal AIM2 Inflammasome Activation After Subarachnoid Hemorrhage.

Authors:  Yonghe Zheng; Wenwen Tang; Hanhai Zeng; Yucong Peng; Xiaobo Yu; Feng Yan; Shenglong Cao
Journal:  Front Neurol       Date:  2022-03-23       Impact factor: 4.003

5.  (-)-Epigallocatechin-3-gallate Inhibits Human and Rat Renal Organic Anion Transporters.

Authors:  Tatsuya Kawasaki; Masaki Kondo; Rioka Hiramatsu; Tomohiro Nabekura
Journal:  ACS Omega       Date:  2021-02-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.